Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PKM | P14618 | 1/20 | 1.00 |
| ▸ | LIG1 | P18858 | 1/20 | 1.00 |
| ▸ | PLAU | P00749 | 1/20 | 0.59 |
| ▸ | DAO | P14920 | 6/20 | 0.54 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | HPGDS | O60760 | 1/20 | 0.41 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.41 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4283377 | 0.88 | PKM (0.79) | PKMLIG1PLAUDAOHPGD | |
| SCHEMBL9373389 | 0.83 | PKM (0.70) | PKMLIG1PLAUDAOHPGD | |
| SCHEMBL25256894 | 0.82 | PKM (0.69) | PKMLIG1PLAUHPGDRAB9A | |
| SCHEMBL3064091 | 0.81 | PKM (0.68) | PKMLIG1PLAUDAOHPGD | |
| SCHEMBL26054440 | 0.78 | PKM (0.63) | PKMLIG1PLAUDAOHPGD | |
| SCHEMBL7827726 | 0.78 | PKM (0.63) | PKMLIG1PLAUDAOHPGD | |
| SCHEMBL28120120 | 0.76 | PKM (0.61) | PKMLIG1PLAUHPGDMEN1 | |
| SCHEMBL16879111 | 0.76 | PKM (0.61) | PKMLIG1PLAUDAOHPGD | |
| SCHEMBL70493 | 0.75 | DAO (0.67) | PKMLIG1DAOHPGDMEN1 | |
| SCHEMBL5982145 | 0.74 | PLAU (1.00) | PKMLIG1PLAU |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 85 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2635567-B1 | INDOLE DERIVATIVES | RICHTER GEDEON NYRT (HU) | 2015-10-28 | — | — | EP | claimed |
| EP-2635567-A1 | INDOLE DERIVATIVES | Richter Gedeon Nyrt. (HU) | 2013-09-11 | — | — | EP | claimed |
| US-20130217702-A1 | INDOLE DERIVATIVES | RICHTER GEDEON NYRT. | 2013-08-22 | — | — | US | claimed |
| WO-2012059776-A1 | INDOLE DERIVATIVES | RICHTER GEDEON NYRT. (HU) | 2012-05-10 | — | — | WO | claimed |
| US-7692005-B2 | Kinase inhibitors | ALLERGAN, INC. (US) | 2010-04-06 | — | — | US | claimed |
| EP-1902025-A1 | KINASE INHIBITORS | Allergan, Inc. (US) | 2008-03-26 | — | — | EP | claimed |
| US-20070032478-A1 | Kinase Inhibitors | ALLERGAN, INC. | 2007-02-08 | — | — | US | claimed |
| WO-2007008895-A1 | KINASE INHIBITORS | ALLERGAN, INC. (US) | 2007-01-18 | — | — | WO | claimed |
| US-20250136570-A1 | HDAC INHIBITORS AND THERAPEUTIC USE THEREOF | TANGO THERAPEUTICS, INC. | 2025-05-01 | — | — | US | disclosed |
| EP-4441033-A1 | NOVEL HDAC INHIBITORS AND THERAPEUTIC USE THEREOF | Tango Therapeutics, Inc. (US) | 2024-10-09 | — | — | EP | disclosed |
| CN-118715206-A | Novel HDAC inhibitors and therapeutic uses thereof | 探戈医药股份有限公司 | 2024-09-27 | — | — | CN | disclosed |
| US-12043607-B2 | HDAC inhibitors and therapeutic use thereof | TANGO THERAPEUTICS, INC. (US) | 2024-07-23 | — | — | US | disclosed |
| US-12043607-B2 | HDAC inhibitors and therapeutic use thereof | TANGO THERAPEUTICS, INC. (US) | 2024-07-23 | — | — | US | disclosed |
| US-12043607-B2 | HDAC inhibitors and therapeutic use thereof | TANGO THERAPEUTICS, INC. (US) | 2024-07-23 | — | — | US | disclosed |
| EP-0393936-B1 | 3-substituted-2-oxindole derivatives as antiinflammatory agents | PFIZER (US) | 1995-02-22 | — | — | EP | disclosed |
| US-5300655-A | 2-carboxy-thiophene derivatives | PFIZER INC. (US) | 1994-04-05 | — | — | US | disclosed |
| US-5290802-A | 3-substituted-2-oxindole derivatives | PFIZER INC. (US) | 1994-03-01 | — | — | US | disclosed |
| US-5047554-A | 3-substituted-2-oxindole derivatives | PFIZER INC. (US) | 1991-09-10 | — | — | US | disclosed |
| EP-0393936-A1 | 3-substituted-2-oxindole derivatives as antiinflammatory agents | PFIZER INC. (US) | 1990-10-24 | — | — | EP | disclosed |
| US-4753941-A | HYPNOTICS, MUSCLE RELAXANTS | RHONE-POULENC SANTE (FR) | 1988-06-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130217702-A1 | INDOLE DERIVATIVES | BDKRB1, BDKRB2, ARRB1 | PKM 2402/4885LIG1 3135/4885PLAU 2538/4885 |
| US-20250136570-A1 | HDAC INHIBITORS AND THERAPEUTIC USE THEREOF | HDAC1, HDAC7, HDAC5 | PKM 511/4885LIG1 3598/4885PLAU 2611/4885 |
| US-12043607-B2 | HDAC inhibitors and therapeutic use thereof | HDAC1, HDAC7, HDAC5 | PKM 511/4885LIG1 3598/4885PLAU 2611/4885 |
| US-20070032478-A1 | Kinase Inhibitors | ABL1, LCK, ERBB2 | PKM 715/4885LIG1 1287/4885PLAU 2515/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.